Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model.
暂无分享,去创建一个
Natalia Vykhodtseva | Nathan McDannold | Muna Aryal | N. McDannold | N. Vykhodtseva | Juyoung Park | Yongzhi Zhang | Juyoung Park | Yong-Zhi Zhang | M. Aryal
[1] Mu-Yi Hua,et al. Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. , 2010, Neuro-oncology.
[2] Yuan Cheng,et al. Experimental Study on Targeted Methotrexate Delivery to the Rabbit Brain via Magnetic Resonance Imaging–Guided Focused Ultrasound , 2009, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[3] F M Muggia,et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Forrest M Kievit,et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[5] W. Pardridge,et al. Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.
[6] Mu-Yi Hua,et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain , 2010, Proceedings of the National Academy of Sciences.
[7] A. Gabizon,et al. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. , 1995, Journal of neurosurgery.
[8] A. Stan,et al. Doxorubicin-induced cell death in highly invasive human gliomas. , 1999, Anticancer research.
[9] N. McDannold,et al. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[10] Yao-Sheng Tung,et al. In vivo transcranial cavitation threshold detection during ultrasound-induced blood–brain barrier opening in mice , 2010, Physics in medicine and biology.
[11] Manabu Kinoshita,et al. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[12] D. Altman,et al. Multiple significance tests: the Bonferroni method , 1995, BMJ.
[13] K. Geiger,et al. Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.
[14] Natalia Vykhodtseva,et al. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. , 2012, Cancer research.
[15] Kullervo Hynynen,et al. Ultrasound insertion loss of rat parietal bone appears to be proportional to animal mass at submegahertz frequencies. , 2011, Ultrasound in medicine & biology.
[16] Kullervo Hynynen,et al. Blood-brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. , 2012, Radiology.
[17] K. Hynynen,et al. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. , 2004, Ultrasound in medicine & biology.
[18] Feng-Yi Yang,et al. Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound , 2012, International journal of nanomedicine.
[19] Natalia Vykhodtseva,et al. The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[20] R. Zhou,et al. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. , 2002, Cancer research.
[21] E. Frenkel,et al. Neurotoxicity of chemotherapeutic agents after blood‐brain barrier modification: Neuropathological studies , 1983, Annals of neurology.
[22] Natalia Vykhodtseva,et al. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. , 2005, Ultrasound in medicine & biology.
[23] M. Michaelis,et al. Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles. , 2011, International journal of pharmaceutics.
[24] Natalia Vykhodtseva,et al. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI‐guided focused ultrasound , 2007, International journal of cancer.
[25] J. Markert,et al. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide , 2011, Journal of medical imaging and radiation oncology.
[26] K. Hynynen,et al. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.
[27] Mu-Yi Hua,et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. , 2010, Radiology.
[28] Rajiv Chopra,et al. Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-β Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease , 2010, PloS one.
[29] D. Mager,et al. Effect of Repetitive Administration of Doxorubicin-Containing Liposomes on Plasma Pharmacokinetics and Drug Biodistribution in a Rat Brain Tumor Model , 2005, Clinical Cancer Research.
[30] Yunhui Liu,et al. Mechanism of Low-Frequency Ultrasound in Opening Blood–Tumor Barrier by Tight Junction , 2011, Journal of Molecular Neuroscience.
[31] D. Amelio,et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[32] Natalia Vykhodtseva,et al. Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. , 2012, Ultrasound in medicine & biology.
[33] M. Fukui,et al. Neurotoxicity of adriamycin passed through the transiently disrupted blood-brain barrier by mannitol in the rat brain , 1987, Brain Research.
[34] W. Pardridge,et al. Blood-brain barrier delivery. , 2007, Drug discovery today.
[35] Stephen Meairs,et al. Self-assembled liposome-loaded microbubbles: The missing link for safe and efficient ultrasound triggered drug-delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[36] K. Hynynen,et al. Targeted disruption of the blood–brain barrier with focused ultrasound: association with cavitation activity , 2006, Physics in medicine and biology.
[37] K. Hynynen,et al. Transcranial Magnetic Resonance Imaging– Guided Focused Ultrasound Surgery of Brain Tumors: Initial Findings in 3 Patients , 2010, Neurosurgery.
[38] V. P. Collins,et al. Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas , 1990, Acta Neurochirurgica.
[39] M. Glatzel,et al. Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects. , 2009, Clinical neuropathology.
[40] J. Simes,et al. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy , 2010, Journal of Clinical Neuroscience.
[41] M. Chamberlain. Radiographic patterns of relapse in glioblastoma , 2010, Journal of Neuro-Oncology.
[42] J. Beijnen,et al. Abstract 5687: Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer , 2012 .
[43] Faith Davis,et al. Brain tumor survival: Results from the National Cancer Data Base , 1998, Journal of Neuro-Oncology.
[44] M. Karamouzis,et al. Intratumoral Doxorubicin in Patients With Malignant Brain Gliomas , 2002, American journal of clinical oncology.
[45] Dai Fukumura,et al. Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize , 2007, Journal of cellular biochemistry.
[46] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[47] G. Vassal,et al. Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[48] Rolf F. Barth,et al. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas , 2009, Journal of Neuro-Oncology.